Evidence mapPaperPMID 40993300Full record

ArticleNPJ digital medicine2025

Developing a thyroid cancer differentiation state classification system using deep residual networks and metabolic signature profiling.

Yanzhi Zhang, Xiaoxue Du, Sijia Cai, Yiming Cao, Dan Zhao, Weibo Xu, Tian Liao, Ning Qu, Rongliang Shi, Qinghai Ji and 2 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yanzhi Zhang *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Xiaoxue Du *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Sijia Cai *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Yiming Cao *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Dan ZhaoDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Weibo XuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Tian LiaoDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Ning QuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Rongliang ShiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Qinghai JiDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Ben MaDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China. doctormaben@163.com.ORCID http://orcid.org/0000-0003-2402-427X
Yu WangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China. neck130@sina.com.ORCID http://orcid.org/0000-0003-2622-294X

Funding

Clinical Research Special Youth Project 20234Y0120Ministry of Science and Technology of the People's Republic of China 2024ZD0525600National Natural Science Foundation of China 82203052National Natural Science Foundation of China 82473361Science and Technology Commission of Shanghai Municipality 22Y21900100Shanghai Anti-Cancer Association SACA-AX202213
6 · The paper itself

Abstract

We developed a deep residual network (ResNet) framework to classify thyroid cancer differentiation states by integrating multiomic data and interpretability analysis. Our framework incorporated untargeted metabolomic, whole-exome sequencing, and transcriptomic data from 158 thyroid tumors and 57 matched normal tissues, encompassing well-differentiated, poorly differentiated, and anaplastic thyroid cancers. We further examined single-cell RNA sequencing datasets from the Gene Expression Omnibus (GEO) to map key metabolic reprogramming pathways in dedifferentiated thyroid cancer. We systematically integrated transcriptomic data from follicular epithelial-derived thyroid carcinomas across all GEO cohorts, establishing a pan-pathological classification model based on a 10-gene metabolic signature. To complement this approach, a 10-metabolite model was developed via the ResNet architecture, capitalizing on the direct pathophysiological responsiveness of metabolites to tumor progression states. By employing Shapley additive explanations, we highlighted critical metabolic signatures driving differentiation states. Our findings reveal how metabolic shifts underpin thyroid cancer progression, and based on these findings, we propose an accurate, interpretable model that may facilitate early diagnosis and inform clinical decision-making.

Identifiers

PMID40993300
PMCPMC12460824

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.